Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Fase III-studie toont meerwaarde TIL aan bij gemetastaseerd melanoom
mrt 2023 | Dermato-oncologie